Selank side effects by evidence tier: what the Russian anxiety trials recorded against benzodiazepine comparators, the sedation and dependence claims, the immune thread, and what is untested.
Selank — the tuftsin analogue Thr-Lys-Pro-Arg-Pro-Gly-Pro — is marketed on a negative claim: an anxiolytic without the sedation, dependence or withdrawal of a benzodiazepine. That claim comes from Russian clinical trials in which Selank was compared directly with benzodiazepines, and how much it can bear depends on how those trials were built. This page reports what they recorded, what the rodent and immune literature adds, and what nobody has measured. It is a research reference beside the Selank profile, not advice.
The pivotal Selank trial, published in the Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova in 2008, enrolled a few dozen patients with generalised anxiety disorder or neurasthenia and compared the 0.15 percent nasal solution, given several times daily for two to three weeks, with the benzodiazepine medazepam. A later Russian comparison used phenazepam. The trials were open-label, and neither had a placebo arm.
That design shapes every safety statement that follows. A comparison against a benzodiazepine can show that Selank produced less sedation than medazepam, and it did. It cannot show that Selank produced no sedation, because there was no untreated group to measure the baseline against, and unblinded patients and raters knew who was receiving the peptide. The same applies to the absence of dependence and withdrawal: the follow-up lasted weeks, not the months over which benzodiazepine dependence is normally assessed. The Selank research overview discusses what these trials show about efficacy; the Selank dosage notes describe how they administered it.
Within those limits, the record is consistent. The 2008 trial and subsequent Russian studies reported no serious adverse events, no sedation, no withdrawal on discontinuation and no dependence, and reported that anxiety scores fell with a faster onset than the comparator. The Russian label lists hypersensitivity and pregnancy as the principal contraindications. An immunology substudy in the same journal in 2008 measured cytokine changes in anxious patients and did not report adverse effects.
The registration in Russia as a prescription nasal solution adds post-marketing years of use in a formulated product. That is evidence that no large safety signal emerged; it says nothing about incidence, and it applies to a sterile 0.15 percent solution at labelled amounts, not to bulk lyophilised peptide.
The mechanism makes the benzodiazepine comparison more than a marketing choice. A 2016 study in Frontiers in Pharmacology reported that Selank altered the expression of genes involved in GABA-A receptor signalling in the mouse brain, with a transcriptional profile that overlapped with a benzodiazepine-like drug, and other work reported that it modulated GABA's affinity for its receptor in vitro. A 2017 study in Behavioural Neurology found that Selank enhanced the anxiolytic effect of diazepam in rats under chronic mild stress.
Read together, these say that Selank touches the same system benzodiazepines act on, and that additive effects with a benzodiazepine are demonstrated in rats. The claim that it lacks the liabilities of that system rests on short Russian clinical observation. It is a plausible claim with support, not an established one, and additive effects with sedatives, alcohol and — given the enkephalinase inhibition reported in 2001 — opioids cannot be excluded.
Selank is built on tuftsin, an immunoglobulin fragment that stimulates phagocytosis, and the literature reports shifts in interleukin-6, interferon and Th1/Th2 balance in animals and in the small Russian substudy. This is the least-examined safety dimension: a compound with immunomodulatory activity could in principle affect autoimmune or infectious conditions, and no study has looked. The rodent anxiety work — elevated plus-maze, open-field and stress models at roughly 0.1 to 0.3 mg/kg, intranasally or intraperitoneally — reported no toxicity but was not designed to detect immune effects.
Research-community reports describe mild nasal irritation with intranasal solutions, transient fatigue or a flattened affect at higher amounts, and occasional headache. None comes from a controlled study; there is no denominator, no blinding and no verification of what the solution contained. They cannot establish incidence or causation, and the flattened-affect reports in particular are the kind of signal an open comparator trial would be unlikely to capture.
Selank is a basic, water-soluble heptapeptide with no cysteine and no methionine, so it is chemically more forgiving than Semax; its vulnerability is proteolysis and, in a spray device, microbial contamination of a repeatedly opened solution. Nasal irritation in unregulated use may trace to synthesis impurities, residual solvents, endotoxin or a solution past its useful life rather than to the peptide. Reading the certificate of analysis for HPLC purity and identity is the only way to separate compound effects from product effects — see lab testing and COAs and the cold-chain and shelf-life guide. The Selank 5 mg vial sold here is third-party HPLC tested by lot. The Semax + Selank 10 mg blend contains 5 mg of each; no study has examined the combination, and the Semax vs Selank comparison sets out the difference.
Selank has no Health Canada market authorisation and no Drug Identification Number; its Russian registration has no standing under Canadian law, and research-grade material is sold in Canada for laboratory use only. The U.S. FDA has not reviewed Selank under its section 503A bulk-substance process, so it is unreviewed there rather than cleared or restricted. Selank is not named on the WADA Prohibited List, though tested athletes should verify with their federation given the list's open categories.
Does Selank cause sedation? The 2008 Russian trial reported less sedation than the benzodiazepine medazepam and described none. Without a placebo arm or blinding, "less than a benzodiazepine" is the claim the data supports; "none" is an observation from an open study.
Is Selank habit-forming? Russian trials reported no dependence or withdrawal over two- to three-week courses. No study has followed patients for the months over which dependence is normally assessed.
Can Selank be combined with benzodiazepines or alcohol? A 2017 rat study found Selank enhanced diazepam's anxiolytic effect, so additive effects are demonstrated in animals. No human study has examined the combination with any sedative or with alcohol.
What side effects do uncontrolled reports describe? Mild nasal irritation, transient fatigue or flattened affect at higher amounts, and occasional headache. These are self-reports without a comparator.
Is this medical advice? No. This page summarises published research for laboratory reference. It is not medical advice, not a safety assurance, and not a dosing recommendation. Selank is sold here for research use only.
